BACKGROUND:GB virus C (GBV-C) infection is transmitted by blood exposure and associated with lower human immunodeficiency virus (HIV) load and slower HIV disease progression. Few studies describe predictors of acute GBV-C infection following transfusion in HIV-infected patients. METHODS: We used a limited-access database from the National Heart Lung and Blood Institute's Viral Activation Transfusion Study, a randomized controlled trial of leukoreduced versus nonleukoreduced transfusions received by HIV-infected, transfusion-naive patients. Blood samples from 489 subjects were tested for GBV-C markers in pretransfusion and posttransfusion samples. We estimated the risk of acquiring GBV-C RNA and predictors of GBV-C acquisition, using pooled logistic regression. RESULTS:GBV-C RNA was detected ≤120 days following the first transfusion in 22 (7.5%) of 294 subjects who were GBV-C negative before transfusion. The risk of GBV-C RNA acquisition increased with each unit transfused (odds ratio, 1.09; 95% confidence interval, 1.06-1.11). Lower baseline HIV load and use of antiretroviral therapy were associated with subsequent GBV-C RNA acquisition, after control for units of blood transfused. Leukoreduced status of transfused units was not associated with GBV-C transmission. CONCLUSIONS: Blood transfusion is associated with a significant risk of GBV-C acquisition among HIV-infected patients. Transmission of GBV-C by blood transfusion was inversely related to HIV load.
RCT Entities:
BACKGROUND:GB virus C (GBV-C) infection is transmitted by blood exposure and associated with lower human immunodeficiency virus (HIV) load and slower HIV disease progression. Few studies describe predictors of acute GBV-C infection following transfusion in HIV-infectedpatients. METHODS: We used a limited-access database from the National Heart Lung and Blood Institute's Viral Activation Transfusion Study, a randomized controlled trial of leukoreduced versus nonleukoreduced transfusions received by HIV-infected, transfusion-naive patients. Blood samples from 489 subjects were tested for GBV-C markers in pretransfusion and posttransfusion samples. We estimated the risk of acquiring GBV-C RNA and predictors of GBV-C acquisition, using pooled logistic regression. RESULTS:GBV-C RNA was detected ≤120 days following the first transfusion in 22 (7.5%) of 294 subjects who were GBV-C negative before transfusion. The risk of GBV-C RNA acquisition increased with each unit transfused (odds ratio, 1.09; 95% confidence interval, 1.06-1.11). Lower baseline HIV load and use of antiretroviral therapy were associated with subsequent GBV-C RNA acquisition, after control for units of blood transfused. Leukoreduced status of transfused units was not associated with GBV-C transmission. CONCLUSIONS: Blood transfusion is associated with a significant risk of GBV-C acquisition among HIV-infectedpatients. Transmission of GBV-C by blood transfusion was inversely related to HIV load.
Authors: Peer B Christensen; Niels Fisker; Lone H Mygind; Henrik B Krarup; Niels Wedderkopp; Kim Varming; Jørgen Georgsen Journal: J Med Virol Date: 2003-05 Impact factor: 2.327
Authors: D Rey; J Vidinic-Moularde; P Meyer; C Schmitt; S Fritsch; J M Lang; F Stoll-Keller Journal: Eur J Clin Microbiol Infect Dis Date: 2000-09 Impact factor: 3.267
Authors: J Xiang; S Wünschmann; D J Diekema; D Klinzman; K D Patrick; S L George; J T Stapleton Journal: N Engl J Med Date: 2001-09-06 Impact factor: 91.245
Authors: Giuseppe Nunnari; Luciano Nigro; Filippo Palermo; Massimo Attanasio; Annemarie Berger; Hans W Doerr; Roger J Pomerantz; Bruno Cacopardo Journal: Ann Intern Med Date: 2003-07-01 Impact factor: 25.391
Authors: Jinhua Xiang; Sarah L George; Sabina Wünschmann; Qing Chang; Donna Klinzman; Jack T Stapleton Journal: Lancet Date: 2004-06-19 Impact factor: 79.321
Authors: Carolyn F Williams; Donna Klinzman; Traci E Yamashita; Jinhua Xiang; Philip M Polgreen; Charles Rinaldo; Chenglong Liu; John Phair; Joseph B Margolick; Dietmar Zdunek; Georg Hess; Jack T Stapleton Journal: N Engl J Med Date: 2004-03-04 Impact factor: 91.245
Authors: Marion C Lanteri; Farnaz Vahidnia; Sylvia Tan; Jack T Stapleton; Philip J Norris; John Heitman; Xutao Deng; Sheila M Keating; Don Brambilla; Michael P Busch; Brian Custer Journal: J Infect Dis Date: 2014-11-25 Impact factor: 5.226
Authors: Farnaz Vahidnia; Maya Petersen; Jack T Stapleton; George W Rutherford; Michael Busch; Brian Custer Journal: Clin Infect Dis Date: 2012-07-02 Impact factor: 9.079
Authors: Steven Kleinman; Michael P Busch; Edward L Murphy; Hua Shan; Paul Ness; Simone A Glynn Journal: Transfusion Date: 2013-11-04 Impact factor: 3.157
Authors: Aniel de Sarom Negrão Silva; Clayton Pereira Silva; Rafael Ribeiro Barata; Pedro Victor Reis da Silva; Patrícia Danin Jordão Monteiro; Letícia Lamarão; Rommel Mário Rodríguez Burbano; Márcio Roberto Teixeira Nunes; Patrícia Danielle Lima de Lima Journal: Virol J Date: 2020-10-14 Impact factor: 4.099